# Conformis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/conformis

- Industry: Medical Devices & Equipment
- Headquarters: Billerica, US
- Website: www.conformis.com
- Total disclosed funding: $263M
- Latest round: Series E (Jun 12, 2012)
- Investors on record: 8

## About

Conformis, Inc. is an innovative medical technology company specializing in personalized, 3D-printed orthopedic implants tailored to meet the unique anatomical needs of individual patients for improved surgical outcomes.Founded in 2004 in Billerica, US, Conformis, Inc. develops custom orthopedic implants. The firm was previously involved in an IPO in June 2015, raising USD 135 mn. Currently, it is set to be acquired by Restor3d, Inc., with the transaction expected to close in late Q3 2023, leading to its delisting from NASDAQ.Conformis, Inc. focuses on creating 3D-printed orthopedic implants that cater to specific patient anatomy. Their offerings include solutions for total ankle replacements, knee applications, and personalized hip implants, utilizing advanced 3D printing technology and AI-driven designs to enhance surgical precision and fit.In 2022, Conformis, Inc. reported a revenue of USD 62.05 mn, with an EBITDA of USD -42.25 mn, reflecting the financial performance of the company during the year.Conformis, Inc. aims to expand its product offerings and market presence following its upcoming acquisition by Restor3d, Inc. The company plans to launch new customized orthopedic solutions and expand into additional markets, particularly in North America and Europe. The funding raised in earlier rounds will support these initiatives, enhancing product development and market reach as the firm transitions into its new structure.

## Funding rounds

- Series E, Jun 12, 2012, $114M — AGC Equity Partners
- Series E, Jan 30, 2012, $89M — AGC Equity Partners, Axel Johnson AB
- Series D, Aug 26, 2010, $25M — Western Technology Investment, Aeris Capital, Thorner Ventures, Veron International, IBT Securities
- Series D, Aug 31, 2009, $35M — Western Technology Investment, CDIB BioScience Venture Management, Aeris Capital, Thorner Ventures, Veron International, IBT Securities

## Investors

- Western Technology Investment (https://capitalatlas.ai/funds/western-technology-investment) — Series D
- CDIB BioScience Venture Management (https://capitalatlas.ai/funds/cdib-bioscience-venture-management) — Series D
- Aeris Capital — Series D
- Thorner Ventures — Series D
- Veron International — Series D
- IBT Securities — Series D
- AGC Equity Partners (https://capitalatlas.ai/funds/agc-equity-partners) — Series E
- Axel Johnson AB — Series E